Scarica l'app Stockscreener
11.89
0.25%
-0.03
Dopo l'orario di chiusura:
12.14
0.25
+2.10%
Precedente Chiudi:
$11.92
Aprire:
$12.25
Volume 24 ore:
40,781
Relative Volume:
0.98
Capitalizzazione di mercato:
$22.35M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.94%
1M Prestazione:
+56.65%
6M Prestazione:
+129.09%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.35
$12.62
Intervallo di 1 settimana:
$11.00
$13.25
Portata 52W:
$2.90
$13.34
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Nome
Neuphoria Therapeutics Inc
Settore
Industria
Telefono
781-439-5551
Indirizzo
100 SUMMIT DR, BURLINGTON
Confronta NEUP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
11.89 | 22.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Reiterato | Maxim Group | Buy |
| 2022-01-10 | Iniziato | Berenberg | Buy |
| 2022-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Iniziato | Evercore ISI | Outperform |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Neuphoria Therapeutics Inc Borsa (NEUP) Ultime notizie
Will Neuphoria Therapeutics Inc. benefit from macro trendsTrade Entry Summary & Precise Buy Zone Identification - Newser
technical analysis overview for neuphoria therapeutics inc. stock2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
What to expect from Neuphoria Therapeutics Inc. in the next 30 days2025 Institutional Moves & Weekly Breakout Stock Alerts - Newser
What data driven models say about Neuphoria Therapeutics Inc.’s futureJuly 2025 Patterns & Stock Market Timing Techniques - Newser
How to integrate Neuphoria Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Reliable Trade Execution Plans - Newser
What to do if you’re stuck in Neuphoria Therapeutics Inc.Share Buyback & AI Enhanced Market Trend Forecasts - Newser
How to build a dashboard for Neuphoria Therapeutics Inc. stockBull Run & Entry Point Confirmation Alerts - Newser
Can you recover from losses in Neuphoria Therapeutics Inc.July 2025 Big Picture & Reliable Entry Point Trade Alerts - Newser
Statistical indicators supporting Neuphoria Therapeutics Inc.’s strength2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
Why is Neuphoria Therapeutics Inc. stock going upPortfolio Update Summary & Expert Approved Trade Ideas - خودرو بانک
Is Neuphoria Therapeutics Inc. being accumulated by smart moneyQuarterly Profit Report & Accurate Intraday Trading Signals - خودرو بانک
Can Neuphoria Therapeutics Inc. recover in the next quarterQuarterly Profit Report & Weekly Market Pulse Updates - Newser
Is Neuphoria Therapeutics Inc. affected by consumer sentimentJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - خودرو بانک
Neuphoria completes enrollment for phase 3 anxiety drug trial By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. outperform the marketWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Can momentum traders help lift Neuphoria Therapeutics Inc.IPO Watch & Safe Capital Preservation Plans - Newser
Analyzing recovery setups for Neuphoria Therapeutics Inc. investorsWeekly Profit Recap & Verified Momentum Watchlists - Newser
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder - MarketScreener
Is Neuphoria Therapeutics Inc. a stock for growth or value investors2025 Investor Takeaways & Capital Protection Trading Alerts - خودرو بانک
Neuphoria completes enrollment for phase 3 anxiety drug trial - Investing.com
Neuphoria Therapeutics achieves target enrollment in AFFIRM-1 Phase 3 trial for BNC-210. - AInvest
Neuphoria Therapeutics Completes Target Enrollment in Phase - GlobeNewswire
Neuphoria Therapeutics Achieves Target Enrollment in Phase 3 AFFIRM-1 Trial for BNC-210 in Social Anxiety Disorder. - AInvest
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) - GlobeNewswire Inc.
Using flow based indicators on Neuphoria Therapeutics Inc.Rate Cut & AI Optimized Trading Strategy Guides - Newser
Chart based exit strategy for Neuphoria Therapeutics Inc.July 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - Newser
Will Neuphoria Therapeutics Inc. continue its uptrend2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Is Neuphoria Therapeutics Inc. attractive for institutional investorsJuly 2025 Trade Ideas & AI Forecasted Entry/Exit Points - خودرو بانک
Technical analysis overview for Neuphoria Therapeutics Inc. stock2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Is it too late to sell Neuphoria Therapeutics Inc.July 2025 Patterns & Daily Technical Stock Forecast Reports - Newser
What is the long term forecast for Neuphoria Therapeutics Inc. stockJuly 2025 Final Week & High Conviction Investment Ideas - خودرو بانک
Has Neuphoria Therapeutics Inc. formed a bullish divergenceEarnings Overview Report & Real-Time Buy Zone Alerts - Newser
How to forecast Neuphoria Therapeutics Inc. trends using time seriesEarnings Trend Report & Stepwise Trade Execution Plans - Newser
Sentiment analysis tools applied to Neuphoria Therapeutics Inc.July 2025 Retail & Safe Capital Investment Plans - Newser
Using portfolio simulators with Neuphoria Therapeutics Inc. included2025 Market Trends & Technical Confirmation Trade Alerts - Newser
Is Neuphoria Therapeutics Inc.’s ROIC above industry average2025 Historical Comparison & Technical Entry and Exit Alerts - خودرو بانک
Exit strategy if you’re trapped in Neuphoria Therapeutics Inc.Weekly Volume Report & Fast Entry and Exit Trade Plans - Newser
Will Neuphoria Therapeutics Inc. benefit from AI trendsPortfolio Return Report & Real-Time Buy Signal Notifications - خودرو بانک
Is Neuphoria Therapeutics Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - Newser
Neuphoria Therapeutics Inc Azioni (NEUP) Dati Finanziari
Non sono disponibili dati finanziari per Neuphoria Therapeutics Inc (NEUP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):